HIHiroyasu Igaki

Hiroyasu Igaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroyasu Igaki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with prostate cancer (SMART PRO trial): protocol for a confirmatory clinical trial

    by Sadamoto Zenda, Tairo Kashihara, Tetsuo Saito, Hiroyuki Okamoto, Noriyuki Kadoya, Takahiro Chiba, Shin-Ei Noda, Takashi Kawaguchi, Keiichi Jingu, Keiko Shibuya, et al.

    Introduction In an MRI-guided linear accelerator (MR-LINAC) system, the planned doses for organs at risk and for tumours are assessed by MR imaging and re-contouring at every treatment. This allows treatment to be safer and more precise by ensuring that it is suitable for the state of the patient’s organs on that day, as well as by allowing images to be acquired during radiation therapy to prevent radiation while organs are in motion. Here, we will conduct a confirmatory study of two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with localised prostate cancer. Methods and analysis This will be a single-arm study to demonstrate the safety and efficacy of ultra-hypofractionated radiation (26 Gy/2 Fr) using an MR-LINAC system in patients with very low-intermediate risk prostate cancer. The primary endpoint will be the incidence of grade ≥2 acute urinary tract adverse events occurring within 90 days of the start of radiation therapy. The sample size has been determined to be 58. Ethics and dissemination This study is performed in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects, published by Japan’s Ministry of Education, Science and Technology and the Ministry of Health, Labour and Welfare and the modified act on the Protection of Personal Information as well as the Declaration of Helsinki. This study was approved by the institutional ethics committee of the National Cancer Center on 20 November 2021. The findings of this trial will be submitted to an international peer-reviewed journal and the key findings will be presented at an international scientific conference. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance. Trial registration number UMIN000049746.


  • Open Access

    Effective treatment of empyema with bronchopleural fistula after esophagectomy by endobronchial embolization using endobronchial Watanabe Spigots

    by Shinsuke Uchida, Hiroyasu Igaki, Takehiro Izumo, Yuji Tachimori

    INTRODUCTION: Empyema and bronchopleural fistula are well known complications after thoracic surgery. We report a case of refractory air leakage of bronchopleural fistula in a patient with empyema that was successfully treated by endobronchial embolization using Endobronchial Watanabe Spigots (EWSs). PRESENTATION OF CASE: A 71-year-old man underwent esophagectomy for primary esophageal cancer. A right empyema with bronchopleural fistula (BPF) developed four months after surgery. Right thoracic drainage tube was inserted. Although the empyema was treated by drainage and anti-biotics therapy, the air leakage was apparent. The chest computed tomography (CT) scan revealed that the bronchopleural fistula existed in the segment 6 and 10. Endobronchial embolization was performed to the responsible bronchus using EWSs. After the EWSs of middle and large sizes were inserted into the B 6 c and B 10 b + c, the air leakage was stopped. The thoracic tube of drainage was removed after endobronchial embolization. Complications due to the EWSs insertion were not observed, and the patient was discharged. DISCUSSION: The management of BPF has evolved over the years. Surgical approach is frequently needed to control the BPF, though endobronchial embolization is effective in closing the BPF in some patients. In our case, EWSs of middle and large size were useful to control air leakage. We safely retried the 2nd endoboronchial embolization using the EWS. The patient had no complication after insertion the EWS again. CONCLUSION: Endobronchial embolization using EWSs was an effective treatment of an empyema with bronchopleural fistula after esophagectomy. Highlights:


  • Surgery for clinical T3 carcinomas of the upper thoracic oesophagus and the need for new strategies

    by H. Igaki, H. Kato, Y. Tachimori, Y. Nakanishi, T. Shimoda

    Background: Patients with T3 carcinomas have a dismal prognosis, even after complete resection of the primary tumour and metastatic nodes. This study focused on the clinicopathological characteristics and outcomes after surgical resection of clinical T3 carcinomas of the upper thoracic oesophagus. Methods: Between January 1988 and February 2000, 888 consecutive patients underwent surgical removal of carcinomas of the thoracic oesophagus or oesophagogastric junction at the National Cancer Centre Hospital, Japan. The case records of 51 consecutive patients with clinical T3 tumours of the upper thoracic oesophagus were analysed retrospectively. Results: No patient received preoperative therapy. Complications occurred in 41 (80 per cent). In‐hospital and 30‐day postoperative mortality rates were 10 and 4 per cent respectively. Gross residual primary tumour or metastasis in regional nodes invading adjacent structures was noted in 14 patients (27 per cent) and incomplete resection including microscopic residual tumour in 23 (45 per cent). Overall 3‐ and 5‐year survival rates were 20 and 12 per cent; median survival was 13·1 months. Conclusion: Surgical resection of clinical T3 carcinomas of the upper thoracic oesophagus is associated with a high postoperative complication rate, incomplete resection and unsatisfactory outcome. Reconsideration of the surgical treatment strategy for these tumours is needed. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.


  • Improved Survival for Patients With Upper and/or Middle Mediastinal Lymph Node Metastasis of Squamous Cell Carcinoma of the Lower Thoracic Esophagus Treated With 3-Field Dissection

    by Hiroyasu Igaki, Yuji Tachimori, Hoichi Kato

    To evaluate the outcomes with 2 and 3 lymph node dissection for patients with squamous cell carcinoma of the lower thoracic esophagus at a single institution. Extensive lymph node dissection, including the upper mediastinum, for carcinoma of the lower thoracic esophagus is advocated as a standard surgical procedure with curative intent in Japan. However, its efficacy remains controversial. From January 1988 to December 1997, 532 patients with carcinomas of the thoracic esophagus underwent transthoracic esophagectomy and extensive lymph node dissection with curative intent at the National Cancer Center Hospital, Tokyo. Of these, 495 (93%) had squamous cell carcinomas. A total of 156 (29%) with tumors of the lower thoracic esophagus were retrospectively analyzed. Of the 156 patients, 55 (35%) underwent 2-field and 101 (65%) underwent 3-field lymph node dissection. The operative morbidity and 30-day and in-hospital mortality rates were 68.0%, 1.3%, and 2.6%, respectively. The overall 5-year survival rate for the entire series was 49.3%. One hundred and seven (69%) had lymph node metastases. Upper and/or middle mediastinal lymph node metastases occurred in 42% of the series. The 5-year survival rate for patients with lymph node metastases in the upper and/or middle mediastinum was 23.3%. Among them, the values after 2- and 3-field lymph node dissection were 5.6% and 30.0%, respectively (P = 0.005). Thirteen (27%) of 48 patients with upper and/or middle mediastinal lymph node metastases treated with 3-field dissection had simultaneous cervical lymph node metastases and their 5-year survival rate was 23.1%. The 3-field approach for extensive lymph node dissection provides better survival benefit for patients with squamous cell carcinoma of the lower thoracic esophagus compared to 2-field lymph node dissection when lymph node metastases are present in the upper and/or middle mediastinum.